Almujtama Alraida Medical Co. (9592) fair value: what the stock is really worth
As of Oct 29, 2026: fair value (intrinsic value) of Almujtama Alraida Medical Co. stock SAR 19.43, price SAR 20.99, upside -7.4%, quality 51 out of 100. Rating: fairly valued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Oct 29, 2026.
How to read this chart
35‑month range 18.00 SAR – 33.92 SAR · fair‑value band 14.57 SAR – 24.29 SAR · the 20.99 SAR price screens above the 19.43 SAR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Oct 29, 2026.
Follow Almujtama Alraida Medical Co. in your weekly email
Every Wednesday you see whether Almujtama Alraida Medical Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Almujtama Alraida Medical Co. operates pharmacies in Saudi Arabia. The company provides pharmaceutical services; and a magazine related to medical and pharmaceutical health field. It also offers its products through online. The company was founded in 2001 and is based in Jeddah, Saudi Arabia.
Stock analysis
Almujtama Alraida Medical Co. (9592) currently trades at 20.99 SAR, while our model-based Fair Value estimate is 19.43 SAR, so the stock looks roughly fairly valued today (gap 8.0%).
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of 30.90 SAR per share, and 11 of the 22 models we run sit above the 20.99 SAR price.
Bear case: the Earnings-Based group reads lowest at 6.46 SAR, and 11 of the 22 models stay below the price. Data coverage for this calculation is medium.
Scenario range: 14.57 SAR (bear) to 24.29 SAR (bull), the price of 20.99 SAR sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 51/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Almujtama Alraida Medical Co. reported revenue of 455M SAR in FY2025 versus 304M SAR in FY2021, a compound +10.5%/yr. Reported net income was 8.4M SAR in FY2025, compounding +1.8%/yr from FY2021.
Key figures
Market cap 200M SAR (≈ $53.3M) Micro · P/E ratio 26.0 · P/S ratio 0.48 · EPS (TTM) −0.0900 SAR · Net margin 1.8% · Return on assets (EBIT) 3.6% · Free cash flow 25.0M SAR · Net debt 168M SAR.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 29 out of 100 (low confidence).
What moves the price
The share trades about 32% below its 52-week high and 17% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 38% fair-value upside, at −7%, 9592 screens richer than that median.
Fair Value models
Bear14.57 SARFair Value 19.43 SARBull24.29 SAR
Price 20.99 SAR · Upside -7.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.70/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+5.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.4%
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+1.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year+1.4%
Dividend (yield on the price)0.0%
Profit margin 2021 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.3% → 2%
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−0.6%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Saudi Arabia: IMF forecast 2.1% a year to 2030, 1.7% from 2016 to 2025) that is about −2.6% a year for the price.
Compare Almujtama Alraida Medical Co. with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceutical Retailers · 52 stocks
Beats the industry median on 3/11 measures
Overall it trails its industry peers.
Valuation
Quality Score51 · Below median
Fair Value upside−7.4% · Below median
Profitability
Return on assets1.6% · Below median
Net margin (12 months)1.8% · Below median
Operating margin (12 months)0.0% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)0.0% · Below median
Dividend yield (12 months)0.0% · Bottom 25%
Valuation Multiplesvs Pharmaceutical Retailers median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Almujtama Alraida Medical Co. Fair Value". https://www.fairvalue-calculator.com/stock/9592
Frequently asked questions
Is Almujtama Alraida Medical Co. (9592) overvalued or undervalued?
As of Oct 29, 2026, our model estimates a fair value of 19.43 SAR versus a price of 20.99 SAR, about −7% upside (fairly valued).
What is the fair value of 9592?
Our model-based fair value for Almujtama Alraida Medical Co. is 19.43 SAR (as of Oct 29, 2026), built from audited fundamentals. The current price: 20.99 SAR.
What is the quality score of 9592?
Almujtama Alraida Medical Co. has a Quality Score of 51/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Almujtama Alraida Medical Co. (9592)?
Our model-based price target is the fair value of 19.43 SAR (as of Oct 29, 2026) from 23 valuation models. Cautious scenario 14.57 SAR, optimistic scenario 24.29 SAR. It is a calculation from audited fundamentals, not an analyst target.
What is the Almujtama Alraida Medical Co. stock forecast for 2026?
Our models put fair value at 19.43 SAR, about −7% upside versus a price of 20.99 SAR (fairly valued). Cautious scenario 14.57 SAR, optimistic scenario 24.29 SAR. The calculation is refreshed regularly with new filings.
What growth is priced into Almujtama Alraida Medical Co. (9592)?
For today's price to be fair in a discounted-cash-flow model, Almujtama Alraida Medical Co. would have to grow free cash flow by -0.6 % per year for five years (discount rate 13.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 4 years revenue grew +10.6 % per year. As of Oct 29, 2026.
What discount rate (WACC) does the fair value of 9592 use?
Our models discount Almujtama Alraida Medical Co. at 13.3 %: a base by market capitalisation (micro), country premium for Saudi Arabia. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Almujtama Alraida Medical Co. that is -0.6 % per year a year over ten years, using the same discount rate (13.3 %) and the same formula as our fair value.
How much growth has Almujtama Alraida Medical Co. (9592) delivered so far?
Over the past 4 years revenue at Almujtama Alraida Medical Co. grew +10.6 % a year. The price currently implies -0.6 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Almujtama Alraida Medical Co. (9592) growing?
The median revenue growth in the sector is +3.7 % a year. That is the yardstick for the growth priced into Almujtama Alraida Medical Co. (-0.6 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Almujtama Alraida Medical Co. (9592)?
The free-cash-flow yield on the price is 12.49 %: that much free cash flow Almujtama Alraida Medical Co. produces per unit of market value. When it exceeds the discount rate of our models (13.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Almujtama Alraida Medical Co. (9592)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Almujtama Alraida Medical Co. it is 19.43 SAR per share (as of Oct 29, 2026), against a price of 20.99 SAR. It is the blended result of 23 valuation models (cash flow, earnings, asset, dividend).
Is Almujtama Alraida Medical Co. stock overvalued or undervalued in 2026?
As of Oct 29, 2026, 9592 trades above its calculated fair value: price 20.99 SAR, fair value 19.43 SAR, a gap of about −7% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 9592?
No. The price is what the market pays today (20.99 SAR); the fair value is what the company's own numbers justify (19.43 SAR). For Almujtama Alraida Medical Co. the two are 1.56 SAR per share apart. That gap is exactly why we show both numbers side by side.
How much is Almujtama Alraida Medical Co. worth?
The market values Almujtama Alraida Medical Co. at about 200M SAR (market capitalisation, as of Oct 29, 2026). Per share that is 20.99 SAR; our models calculate a fair value of 19.43 SAR per share.
What do the bullish and bearish scenarios say about 9592?
Our models span a range for Almujtama Alraida Medical Co.: cautious scenario 14.57 SAR, base 19.43 SAR, optimistic 24.29 SAR per share (as of Oct 29, 2026, price 20.99 SAR). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 9592?
Almujtama Alraida Medical Co. trades at a price-to-earnings ratio of 26.0 (as of Oct 29, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 19.43 SAR is built from several models across several years. Other multiples: P/B 0.4, EV/EBITDA 4.3.
How far is 9592 from its 52-week high?
Almujtama Alraida Medical Co. trades at 20.99 SAR, about 32% below its 52-week high of 30.85 SAR and 17% above the low of 18.00 SAR (as of Oct 29, 2026). Distance from the high says nothing about value: that is what the fair value of 19.43 SAR is for.
Which stocks are comparable to Almujtama Alraida Medical Co.?
From the same area (Healthcare) we also value JD Health International Inc, Alibaba Health Information Technology Limited, Yifeng Pharmacy Chain Co, DaShenLin Pharmaceutical Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Almujtama Alraida Medical Co. stock attractive at the current price?
The data as of Oct 29, 2026: price 20.99 SAR, calculated fair value 19.43 SAR (−7%), Quality Score 51/100, from 23 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 9592 calculated?
We run Almujtama Alraida Medical Co. through 23 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 19.43 SAR, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.1 % above its aggregate fair value. Almujtama Alraida Medical Co. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Almujtama Alraida Medical Co. (9592)?
The closing price on Oct 29, 2026 was 20.99 SAR. Our model-based fair value is 19.43 SAR, about −7% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Almujtama Alraida Medical Co. right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. The price sits in the upper half of our model range, so the margin of safety is thin. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Key figures of Almujtama Alraida Medical Co.
How large is the market capitalisation of Almujtama Alraida Medical Co. (9592)?
The market capitalisation of Almujtama Alraida Medical Co. is 200M SAR (≈ $53.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Almujtama Alraida Medical Co. (9592)?
The price-to-sales ratio of Almujtama Alraida Medical Co. is 0.48 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Almujtama Alraida Medical Co. (9592)?
Earnings per share at Almujtama Alraida Medical Co. are −0.0900 SAR (price ÷ EPS = P/E 26.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Almujtama Alraida Medical Co. (9592)?
The net margin of Almujtama Alraida Medical Co. is 1.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the EBIT return on assets of Almujtama Alraida Medical Co. (9592)?
On an EBIT basis the return on assets of Almujtama Alraida Medical Co. is 3.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much net debt does Almujtama Alraida Medical Co. (9592) carry?
The net debt of Almujtama Alraida Medical Co. is 168M SAR (fiscal year 2024, ≈ 6.7 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Almujtama Alraida Medical Co. in the live analysis
One click puts Almujtama Alraida Medical Co. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
Some data
Oct 29, 2026